Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration to advance diagnostics and precision medicine across Southeast Asia, Australia, and New Zealand. This partnership brings together Mayo's global clinical and diagnostic expertise with PAH's regional healthcare network and market knowledge. The collaboration aims to broaden access to advanced molecular and genomic testing, enabling healthcare providers to integrate clinically relevant genomic insights into more personalized patient care.
The partnership will focus on genomics, delivered through LifeStrands Genomics, a subsidiary of PAH. Mayo Clinic Laboratories and LifeStrands Genomics will work together to expand access to advanced molecular and genomic testing, with applications spanning the identification of genetic conditions, disease risk assessment, diagnosis, and treatment planning. LifeStrands Genomics will operate as "LifeStrands in collaboration with Mayo Clinic Laboratories" in certain markets, reflecting the organizations' shared commitment to expanding access to advanced genomic testing and precision medicine.
William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, has been appointed Scientific Adviser to PAH. Dr. Morice emphasized that the collaboration reflects Mayo Clinic Laboratories' commitment to a long-term strategic relationship that unites complementary strengths in laboratory diagnostics and genomics. The partnership aims to bring advanced diagnostic capabilities closer to patients and equip healthcare providers with the insights needed to deliver personalized care.
Christopher Ting, M.D., founder and CEO of Pathology Asia Holdings, noted that Mayo Clinic Laboratories' investment marks an important milestone in their relationship and a strong foundation for the next phase of diagnostic innovation across the region. The partnership combines Mayo Clinic Laboratories' global clinical and scientific expertise with PAH's regional diagnostic capabilities and network, enabling them to broaden access to advanced testing and increase access to genomics and precision medicine capabilities.
Mayo Clinic Laboratories is a global leader in turning test results into clinical answers, providing advanced testing and pathology services for healthcare organizations worldwide. The organization offers more than 4,400 tests and pathology services, delivering specialized diagnostic expertise to help healthcare providers make informed decisions and improve patient care. Pathology Asia, on the other hand, is a leading regional provider of pathology and laboratory diagnostics services, with operations across Singapore, Malaysia, Indonesia, Thailand, Vietnam, the Philippines, and Australia.
LifeStrands Genomics is a leading Asia-Pacific clinical genomics company comprising three specialist laboratories: LifeStrands Genomics Singapore, LifeStrands Genomics Australia, and DNA Laboratories. The group provides advanced molecular and genomic testing across oncology, reproductive health, inherited disorders, and wellness. Operating through CAP- and ISO 15189-accredited laboratories, LifeStrands Genomics delivers clinically actionable insights that empower healthcare professionals to make informed decisions, advance personalized care, and improve patient outcomes.
The collaboration between Mayo Clinic Laboratories, Pathology Asia Holdings, and LifeStrands Genomics is expected to drive innovation in diagnostic capabilities and precision medicine across Southeast Asia, Australia, and New Zealand. The partnership will pursue joint scientific initiatives, education, and thought leadership to support the integration of genomics into patient care. Key aspects of the partnership include expanding access to advanced molecular and genomic testing, improving patient outcomes, and enhancing personalized care.
Key points
- Mayo Clinic Laboratories partners with Pathology Asia Holdings and LifeStrands Genomics to advance diagnostics and precision medicine in Southeast Asia, Australia, and New Zealand.
- The partnership aims to broaden access to advanced molecular and genomic testing, enabling healthcare providers to integrate clinically relevant genomic insights into more personalized patient care.
- The collaboration combines complementary strengths in laboratory diagnostics and genomics to drive innovation in diagnostic capabilities and precision medicine.
